After receiving a positive pcr test on 09-MAY-2022; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (After receiving a positive pcr test on 09-MAY-2022) in a 54-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for Product used for unknown indication: Johnson and Johnson. Past adverse reactions to the above products included No adverse event with Johnson and Johnson. Concurrent medical conditions included Rheumatoid arthritis, Fibromyalgia, Asthma, Anaphylaxis, Cold urticaria and Allergy to NSAIDs. Concomitant products included ADALIMUMAB (HUMIRA), METHOTREXATE, HYDROXYCHLOROQUINE SULFATE (PLAQUENIL [HYDROXYCHLOROQUINE SULFATE]) and DOXEPIN for an unknown indication.    On 20-Nov-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 09-May-2022, the patient experienced COVID-19 (After receiving a positive pcr test on 09-MAY-2022). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 09-May-2022 to 13-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (After receiving a positive pcr test on 09-MAY-2022) had not resolved.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 09-May-2022, SARS-CoV-2 test: positive (Positive) Positive.         It was reported that COVID symptoms first appeared on 07-May-2022, After receiving a positive PCR test on 09-May-2022, she was placed on Paxlovid. On 13-May-2022, patient stopped Paxlovid and was pretty much symptom free except for occasion bouts of tiredness and an occasional cough. The last necessary dose of cough medicine was taken on 14-May-2022. On 18-May-2022 (12 days after first symptoms) patient cough started to come back. The patient was taking any other medications/products within 2 weeks of starting COVID-19 treatment. Patient was put on penicillin as it was either a secondary infection or eventually be considered long COVID. The physician did not mentioned it was the post Paxlovid rebound and advised that, if symptoms continues then to perform chest X-ray.  Company comment- This spontaneous case concerns a 54-year-old female patient with no relevant medical history, who experienced the unexpected non-serious adverse event of special interest COVID-19 (with a positive SARS-CoV-2 test) that occurred 5 months and 4 weeks after receiving the first dose of mRNA-1273 Vaccine. The patient tested positive on polymerase chain reaction test for Covid-19 2 days after the symptoms appeared. She was then given paxlovid which she finished after 5 days. The patient would still occasionally have bouts of fatigue and occasional cough. 5 days after finishing her course of paxlovid,  her cough recurred. She sought consult with a physician thru telehealth who considered a secondary infection of long Covid. She was given Penicillin and was advised to do a chest imaging if the cough will persist. Outcome of the events was not resolved at the time of this report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.; Sender's Comments: This spontaneous case concerns a 54-year-old female patient with no relevant medical history, who experienced the unexpected non-serious adverse event of special interest COVID-19 (with a positive SARS-CoV-2 test) that occurred 5 months and 4 weeks after receiving the first dose of mRNA-1273 Vaccine. The patient tested positive on polymerase chain reaction test for Covid-19 2 days after the symptoms appeared. She was then given paxlovid which she finished after 5 days. The patient would still occasionally have bouts of fatigue and occasional cough. 5 days after finishing her course of paxlovid,  her cough recurred. She sought consult with a physician thru telehealth who considered a secondary infection of long Covid. She was given Penicillin and was advised to do a chest imaging if the cough will persist. Outcome of the events was not resolved at the time of this report. The benefit-risk relationship of mRNA-1273 Vaccine is not affected by this report.